Loading company…
Wenda Pharmaceutical develops small-molecule targeted drugs for cancer and other diseases.
Established in 2013 and based in Ningbo, China, Wenda Pharmaceutical researches and develops small-molecule targeted drugs. Its programs include BET and TYK2 inhibitors and KRAS-targeted drugs for cancer, psoriasis, rheumatoid arthritis, and IBD. Founder Wang Nenghui has 25 years of R&D experience at overseas multinational pharmaceutical companies.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in